Stockscreener 앱 받기
130.40
0.03%
-0.04
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Europe Behavioral Health Market Size to Capture USD 63.23 Billion by 2034 - GlobeNewswire Inc.
Why Novartis Stock Topped the Market Today - sharewise.com
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth - Finviz
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts - Sahm
Morgan Stanley Upgrades Novartis (NVS) to Overweight, Raises Price Target to CHF 110 - Finviz
Net margin % of Novartis AG Sponsored ADR – HAM:NOTA - TradingView
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint - Finviz
Novartis Issues $6 Billion in Debt Securities to Bolster Financial Strategy - The Globe and Mail
Novartis' Strong Branded Drug Portfolio Supports Steady Long-Term Growth - Morningstar
Novartis ADR earnings missed by $0.02, revenue topped estimates - Investing.com India
Novartis completes acquisition of Tourmaline Bio - Novartis
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours - Sahm
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition - Finviz
Novartis announces expiration of Tourmaline Bio tender offer - Novartis
Stocks Rally on US-China Preliminary Trade Agreement - Barchart.com
Avidity Biosciences Soars After $72 Per Share Novartis Takeover - Sahm
Market movers: Qualcomm, Avidity Biosciences, Lululemon, Keurig Dr Pepper… - Proactive financial news
Novartis to acquire Avidity Biosciences in $12B deal - Proactive financial news
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal - Sahm
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket - Benzinga
Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline - Novartis
Jim Cramer: Time To 'Pull The Trigger' On Kratos, A 'Terrific' Stock - Sahm
Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain - Sahm
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer - Novartis
Will Positive Regulatory Updates Further Boost INCY Stock? - The Globe and Mail
Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial - Sahm
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Sahm
Novartis Strengthens Kidney Disease Pipeline With Promising Data - Sahm
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape - Sahm
Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears - Sahm
Will the Orbital Acquisition Strengthen BMY's Cell Therapy Portfolio? - The Globe and Mail
UBS Reaffirms Their Hold Rating on Novartis AG (NOVN) - The Globe and Mail
0.19%
1.31%
자본화:
|
볼륨(24시간):